The goals of the core are to provide all projects with centralized leadership and administrative support, andto ensure effective communication among all projects and cores. The Adminstrative core will be responsiblefor integrating all components of the SPORE and overseeing progress, so that the translational objectivesare being met.To achieve these goals the core will arrange internal group meetings including the monthlyinvestigator meeting, executive committee meetings and invited research lectures. It will provide assistanceto each project and core leader with budgetary issues and issues related to translation to the clinic, and hasdiscretionary funds to support new research opportunities or unexpected costs. It will also oversee theoverall fiscal and budgetary management of the SPORE.This core will also co-ordinate oversight of the SPORE by convening meetings of the Internal and ExternalAdvisory Boards and implementing their recomendations. It will also co-ordinate administration of theDevelopmental Research Program and Career Development Program and ensure that the objectives ofthese programs are beingmet.Finally, the Administrative Core will communicate with the NCI SPORE Program Staff and organizeattendance at the annual SPORE meeting and encourage inter-SPORE collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA126752-01
Application #
7253730
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2007-04-01
Project End
2012-03-31
Budget Start
2007-04-01
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$118,476
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Brunetti, Lorenzo; Gundry, Michael C; Kitano, Ayumi et al. (2018) Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. J Vis Exp :
Xiong, Wei; Chen, Yuhui; Kang, Xi et al. (2018) Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther 26:963-975
Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Velasquez, Mireya Paulina; Bonifant, Challice L; Gottschalk, Stephen (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131:30-38
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Ngai, Ho; Tian, Gengwen; Courtney, Amy N et al. (2018) IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol 201:2141-2153
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139

Showing the most recent 10 out of 270 publications